Despite a significant improvement in natriuretic peptides, no significant improvement in cardiovascular death or HFH was observed in the eight months of follow-up, despite a significant trend in favor of sacubitril-valsartan.
← all excerpts
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon.
1
—
—